Provided herein are compositions and methods comprising engineered microorganisms and their use for locally degrading an antibiotic in the gastrointestinal tract to prevent or limit death of beneficial flora.

The aim of the present invention is a method for the preparation of anallergic probiotic bacterial cultures.

A food or a drink, including: Enterococcus faecium R30 strain (NITE BP-01362) or a processed product thereof; and at least one additive selected from the group consisting of a sweetener, a bittering agent, and acidulant. A method for promoting expression of PGC-1 protein, or preventing conversion of a slow twitch muscle into a fast twitch muscle, the method including: administering Enterococcus faecium R30 strain (NITE BP-01362) or a processed product thereof to a subject in need thereof.

The present disclosure provides engineered modified strains of Enterococcus faecalis (EF) that is able to produce bacteriocin but is inefficient at establishing long-term colonization of the GI track in an animal. Compositions comprising the modified strain and methods of use are also disclosed.

The present invention relates to a method for preparing a camembert type cheese using a well-defined starter culture.

A fermentation of a milk source with Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4404) or a Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4405) to form a fermented milk product. The fermented milk product has at least a cream flavour and aroma. The fermented milk product can be in the form of a powder or a concentrate. The fermented milk product has applications in the food industry. A use of a lactic acid bacterium, Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4404) or a Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4405) for the manufacture of butter-cream flavouring milk ingredients containing at least one of diacetyl, acetoin and 3,4-dihydroxy-3,4-dimethyl-2,5-hexanedione.

The present invention belongs to the field of the biotechnology, and relates to novel Streptococcusbacteria which are useful as antimicrobial agents, particularly against caries and periodontal disease. The invention relates to compositions and functional food comprising the novel bacteria. In particular, the present invention relates to a novel bacterial strain, deposited at the Coleccin Espaola de Cultivos Tipo, with accession number CECT 9174, which has proven to be useful in the prevention and treatment of caries and periodontal disease.

Bacteriophage Insensitive Mutants (BIMs) of three Streptococcus thermophilus parent strains were generated and characterized for phage sensitivity, sedimentation rate, cell chain length, phage adsorption and CRISPR loci alterations. Several BIMs showed an altered sedimentation phenotype as well as an increase cell chain length, reduced phage sensitivity, reduced phage adsorption and 100% identity in three CRISPR loci. The results show that the derived BIMs have become phage-resistant through a mechanism other than CRISPR.

Provided are Enterococcus lactis, a drug for preventing or treating tumor, and use thereof, relating to the technical field of biomedicines. Novel Enterococcus lactis is separated and chosen, and the Enterococcus lactis has an important influence on the effect of tumor immunotherapy for cancer patients. Gut microorganisms and immune cells can interact with each other to jointly regulate the human immune system. The provided Enterococcus lactis can induce the differentiation and maturation of iDC (immature DC) cells, and mature DC can effectively activate T cells and increase the infiltration of tumor infiltrating lymphocytes having anti-tumor activity, thereby killing tumor cells. In addition, the provided Enterococcus lactis can induce the differentiation of M0 type macrophages into M1 or M2 type cells.

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and/or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.